With facilities in both Canada and the US, Altasciences Clinical Research offers comprehensive early stage clinical drug development services in Phase I/ II, including the necessary support services required in this critical stage of drug development. We offer the highest quality services to our international customer base of pharmaceutical, biotechnology and generic companies, with a focus on customer service.
Our clinical pharmacology units are known for the rapid recruitment of healthy normal volunteers and patient populations as well as expeditious study start-up timelines, which are unmatched in the industry. Examples of our population and therapeutic indication experience include:
- Abuse Liability
- Analog Classroom (ADHD)
- Central Nervous System
- Cognitive Testing
- Healthy Normal Volunteers
- Metabolic Disorders
- Pain and Inflammation
- Post-Menopausal Women
- Sleep Disorders
- Substance Abuse
- Women’s Health
We also offer several specialized areas of expertise beyond traditional early development design.
We are an industry leader in the conduct of substance abuse clinical trials, including opioids (oral and nasal snorting), sedative hypnotics and stimulants. Our access to a large database of substance abusers and recreational drug users allows for rapid study enrollment and start-up.
Early Cardiac Safety Assessment
Our experience using High Precision QT Analysis allows sponsors to receive TQT-like statistical power in early phase clinical trials. This allows sponsors to de-risk drug candidates by receiving a more precise indicator of arrhythmia liability prior to late stage development investment, thus saving considerable time and money.
The expertise we provide sponsors on the design and execution of driving simulation studies helps to evaluate the effects of psychoactive and non-psychoactive drugs on the ability to operate a motor vehicle.